<DOC>
	<DOCNO>NCT01820767</DOCNO>
	<brief_summary>Use Paricalcitol stage Vd Chronic Kidney Disease patient , effect inflammatory oxidative stress parameter .</brief_summary>
	<brief_title>Paricalcitol Over Inflammatory Parameters Chronical Kidney Disease Patients</brief_title>
	<detailed_description>Use Paricalcitol stage Vd Chronic Kidney Disease patient use permanent catheter due haemodialysis ; effect inflammatory oxidative stress parameter . This study use paricalcitol ( vitamin D ) versus atorvastatin versus paricalcitol plus atorvastatin treatment .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Vd CKD patient use haemodialysis 3 month . Tunnelizedbearer permanent catheter haemodialysis last 6 month previous begin study . . Kt stable , 45 litre sexs . Patients treatment wiht atorvastatin Patients without infectious inflammatory process 8 week . Two consecutive PTH &lt; 400 pg/ml ; Ca &lt; 10.2 P &lt; 7.0 mg/dl . Patients &gt; 18 year . Pregnant woman . Patients hospitalize 4 week begin treatment . Immunosuppressor intake .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Vd-stadium .</keyword>
	<keyword>Inflammatory pattern</keyword>
	<keyword>Paricalcitol</keyword>
	<keyword>Atorvastatin</keyword>
</DOC>